Editas Medicine (EDIT) EBITDA (2015 - 2025)
Editas Medicine (EDIT) reported EBITDA of -$24.5 million for Q3 2025, up 62.62% year-over-year from -$15.1 million in Q3 2024, and up 52.37% quarter-over-quarter from -$51.5 million in Q2 2025.
Editas Medicine (EDIT) EBITDA (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of EBITDA data on file, last reported at -$24.5 million in Q3 2025.
- EBITDA for Q3 2025 came in at -$24.5 million, up 62.62% year-over-year; the trailing twelve-month figure through Sep 2025 was -$198.8 million (up 12.99% YoY), and the FY2024 annual result was -$251.2 million, down 48.45% from the prior year.
- EBITDA advanced to -$24.5 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$24.0 million in Q4 2023 and troughed at -$76.2 million in Q1 2025.
- A 5-year average of -$52.2 million and a median of -$51.5 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2021 and 2025: EBITDA slumped 536.68% in 2021, then soared 62.62% in 2025.
- A 5-year view of EBITDA shows it stood at -$41.6 million in 2021, then slumped by 52.48% to -$63.4 million in 2022, then jumped by 62.23% to -$24.0 million in 2023, then plunged by 94.45% to -$46.6 million in 2024, then jumped by 47.31% to -$24.5 million in 2025.
- Business Quant data shows EDIT's EBITDA at -$24.5 million in Q3 2025, -$51.5 million in Q2 2025, and -$76.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.55 Mn |
| Jun 30, 2025 | -51.54 Mn |
| Mar 31, 2025 | -76.16 Mn |
| Dec 31, 2024 | -46.59 Mn |
| Sep 30, 2024 | -65.67 Mn |
| Jun 30, 2024 | -71.90 Mn |
| Mar 31, 2024 | -66.99 Mn |
| Dec 31, 2023 | -23.96 Mn |
| Sep 30, 2023 | -50.16 Mn |
| Jun 30, 2023 | -44.09 Mn |
| Mar 31, 2023 | -50.96 Mn |
| Dec 31, 2022 | -63.45 Mn |
| Sep 30, 2022 | -57.52 Mn |
| Jun 30, 2022 | -54.23 Mn |
| Mar 31, 2022 | -50.75 Mn |
| Dec 31, 2021 | -41.61 Mn |
| Sep 30, 2021 | -39.25 Mn |
| Jun 30, 2021 | -55.40 Mn |
| Mar 31, 2021 | -56.88 Mn |
| Dec 31, 2020 | -65.87 Mn |